Eli Lilly and Company

Merrell Dow Pharmaceuticals

Merrell Pharmaceuticals, Inc.

Aventis Pharmaceuticals Inc.

Other

Hoechst Marion Roussel

Ligand Pharmaceuticals, Inc.

Alan M Warshawsky

Gary A Flynn

Douglas Wade Beight

Shujaath Mehdi

John F French

Lynn Stacy Gossett

Quanrong Shen

Peter Rudolph Manninen

Michael John Janusz

John H Kehne

Dawn Alisa Brooks

Donald Paul Matthews

Ying Kwong Yee

Samuel James Dominianni

Robert J Ardecky

Christopher J Rito

Guoxin Zhu

Scott Eugene Conner

Tianwei Ma

Michael James Genin

Jason Matthew Ochoada

Philippe Bey

Leonard Larry Winneroski, Jr

Edward D Daugs

Timothy Paul Burkholder

Sunil Nagpal

Michael Gregory Bell

Nathan Bryan Mantlo

Anthony John Shuker

Pierre-Yves Michellys

Jeremy Schulenburg York

Eugene L Giroux

John S Tyhonas

Jianliang Lu

Ryan Edward Stites

Peter Ambrose Lander

Lindsay Stelzer

Matthew Allen Schiffler

David A Hay

Robert Anthony Doti

Matthew Joseph Fisher

Yanping Xu

Michael LeRoy Phillips

Edward David Mihelich

Winton Dennis Jones, Jr

Alexander Glenn Godfrey

Daryl Lynn Smith

Steven Lee Kuklish

Ana Belen Bueno Melendo

Allie Edward Tripp

Jose Alfredo Martin

Joseph P Burkhart

Meena V Patel

James Robert Henry

Jose Eduardo Lopez

Daniel Ray Mayhugh

Jeffrey Michael Schkeryantz

Ramalinga M Dharanipragada

Maria-Jesus Blanco-Pillado

Jonathan Edward Green

Francisco Javier Agejas-Chicharro

Michael John Rupp

Rafael Ferritto Crespo

Tainwei Ma

Jennifer Ann Vance

James Allen Knobelsdorf

Xiaodong Wang

Carlos Lamas-Peteira

Tatiana Natali Vetman

Lourdes Prieto

Fucheng Qu

Katherine Marie Partridge

Maria Dolores Martin-Ortega Finger

Joseph T Tsay

Isabel Rojo

Maria Jesus Blanco-Pillado

Isabel Rojo Garcia

Maria Rosario Gonzales Garcia

Alicia Torrado

Maria Martin-Ortega Finger

Christopher John Rit

Jian Shen

Matthew Scott Dowling

Gary Alan Flynn

Chahrzad Montrose-Rafezadeh

Anne-Reifel Miller

Phillipe Bey

Jiu-Tsair Tsay

Lindsay Scott Stelzer

The present invention provides a compound of the Formula I: wherein A is: and W, Y, X, R, R, R, and Rare as defined herein, or a pharmaceutically acceptable salt thereof, for use as an inhibitor of the EP4 receptor. 

Dimethylbenzoic acid compounds

The present invention provides compounds of Formula (1), or a pharmaceutically acceptable salt thereof, formula (1), where R, R1, and G are as described herein; methods of preparing the compounds; and use of the compounds to treat pain and/or inflammation associated with arthritis or osteoarthritis. 

[object Object]

The present invention provides a compound of the Formula (I): wherein X, R, R, R, R, R, R, R, R, R, and Rare as defined herein, or a pharmaceutically acceptable salt thereof. 

Phenoxyethyl cyclic amine derivatives and their activity as EP4 receptor modulators

The present invention provides a compound of the Formula I: or a pharmaceutically acceptable salt thereof.

Phenoxyethoxy compounds

Compounds of formula (I): formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and diseases related to dyslipidemia. 

Compounds and methods for modulating FXR

Compounds of formula (I) wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases. 

The present invention relates to novel, non-secosteroidal, phenyl-naphthalene compounds of Formula (I): wherein R, R1, RP, Z, L, LL, RP, RN, and Zare defined herein, their preparation, pharmaceutical compositions, and methods of use. 

Vitamin D receptor modulators

The present invention relates to novel, non-secosteroidal, phenyl-benzothiophene compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1&#x3b1;,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Compounds of formula and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases. 

Compounds and methods for modulating FX-receptors

Compounds of formula wherein variables are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and related diseases. 

FXR agonists

The present invention relates to novel, non-secosteroidal, phenyl-benzoxazole compounds of Formula (I) wherein the variables R, R', RP, RP, L, L, ZP, RB, RB&#x2032;, Land Zare as hereinafter defined, their preparation, pharmaceutical compositions, and methods of use.

The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases. 

Sulfonamide derivatives as PPAR modulators

The present invention relates to novel, non-secosteroidal, phenyl-benzofuran compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1&#x3b1;,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

Compounds represented by the following structural formula (I), and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R1 is an unsubstituted or substituted aryl, heteroaryl, cycloalkyl, aryl-alkyl, heteroaryl-alkyl or cycloalkyl-alkyl, R2 is H, alkyl or haloalkyl, the polymethylene chain (II), is saturated or may contain a carbon-carbon double bond, while n is 2, 3, 4, W is O or S, Y is an unsubstituted phenylene, naphthylene or 1, 2, 3, 4 tetrahydronaphthylene, R3 is II, alkyl or haloalkyl, R4 is II, alkyl, haloalkyl or a substituted or unsubstituted benzyl, are useful for modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus.

Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists

Growing community of inventors

Carmel, IN, United States of America

Alan M Warshawsky